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1460Serious Infection Risk and Immune Recovery after
Double-Unit Cord Blood Transplantation Without
Antithymocyte Globulin
Craig Sauter,1,6 Michelle Abboud,2 Xiaoyu Jia,3 Glenn Heller,3 Anne-Marie Gonzales,1
Marissa Lubin,1 Rebecca Hawke,1 Miguel-Angel Perales,1,6 Marcel R. van den Brink,1,6
Sergio Giralt,1 Genovefa Papanicolaou,4,6 Andromachi Scaradavou,5
Trudy N. Small,5,6 Juliet N. Barker1,6Factors contributing to infection risk after cord blood transplantation (CBT) include the use of anti-thymo-
cyte globulin (ATG), prolonged neutropenia, and failure to transfer immunity. In the present study, we inves-
tigated the potential of double-unit CBTwithout ATG to reduce the risk of infection and evaluated the nature
of serious infections in the first year after CBTusing this approach. Seventy-two predominantly adult patients
underwent CBT for hematologic malignancies; of these, 52 patients received myeloablative conditioning, and
20 received nonmyeloablative conditioning. The peak incidences of bacterial infections (32%), fungal infec-
tions (14%), and bacterial/fungal pneumonias (10%) occurred in the first 30 days posttransplantation. Three
such infections contributed to early mortality. The peak incidence of viral infections was 31-60 days post-
transplantation, affecting 30% of patients. Cytomegalovirus (CMV) was the most common viral infection.
CMV infections occurring before day 120 (n 5 23) had no relationship with graft-versus-host disease
(GVHD), whereas CMV infections occurring after day 120 (n5 5), along with all cases of Epstein-Barr virus
viremia (n 5 5) and adenoviral enteritis (n 5 2), occurred exclusively in the context of GVHD therapy or
corticosteroid use for another indication. Viral infections had the highest lethality: 2 were a direct cause
of death, and 3 contributed to death. Patients exhibited steady immune recovery, achieving a median
CD3141 T cell count .200 cells/mL by day 120 post-CBT, and no infection-related deaths occurred after
day 120. Our results suggest that double-unit CBTwithout ATG is associated with prompt T cell recovery,
and, unlike in CBT incorporating ATG, infection is rarely a primary cause of death. However, CBTwithout
ATG is associated with a significant risk of GVHD, and serious infections remain a challenge, especially in the
setting of GVHD. New strategies are needed to further reduce infectious complications after CBT; these will
require earlier neutrophil recovery and more effective prevention of GVHD, ideally without the profound
T cell depletion associated with ATG therapy.
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been effective in decreasing the incidence and
lethality of bacterial and fungal [3] infections. Viral
infections after CBT are a particular challenge due to
failure to transfer memory immunity [4] and the inad-
equacy and/or toxicity of currently available antiviral
therapies. Further, the risk of viral infection can be
exacerbated by the inclusion of anti-thymocyte
globulin (ATG) in the preparative regimen [5-9].
Consequently, we are currently investigating double-
unit CBTwithout ATG in all CBT recipients with he-
matologic malignancies at Memorial Sloan-Kettering
Cancer Center in an effort to both augment engraft-
ment and reduce the risk of lethal infections. Here,
we report the frequency andnature of serious infections
in thefirst year after double-unitCBTwithoutATG, as
well as immune recovery as measured by absolute lym-
phocyte counts, CD3141 and CD3181 T cell counts,
and phytohemagglutinin-P (PHA-P) responses.METHODS
Patient and Graft Characteristics
This analysis included all consecutive recipients of
a first allogeneic CBT at Memorial Sloan-Kettering
Cancer Center for the treatment of hematologic ma-
lignancies between October 1, 2005, and May 31,
2009 (n 5 72). All patients provided Institutional Re-
view Board–approved informed consent for analysis of
transplantation outcomes. The median follow-up
among survivors was 20 months (range, 4-48 months).
Patient and graft characteristics are summarized in
Table 1. The patients had a diagnosis of high-risk or
advanced hematologic malignancies, with a median
age of 36 years (range, 1-66 years). They receivedTable 1. Patient and Graft Characteristics
Total number 72
Males, n (%) 41 (56)
Age, years, median (range) 36 (1-66)
Weight, kg, median (range) 68 (7-109)
Diagnosis, n (%)
Acute leukemia 37 (51)
Myelodysplastic syndrome/chronic
myelogenous leukemia
3 (4)
Non-Hodgkin lymphoma/chronic
lymphocytic leukemia
22 (31)
Hodgkin lymphoma 10 (14)
Conditioning, n (%)
Myeloablative 52 (72)
Nonmyeloablative 20 (28)
Previous autologous transplantation, n (%) 14 (19)
Recipient CMV seropositive, n (%) 39 (54)
Recipient EBV seropositive, n (%) 63 (88)
HLA-A and -B antigen, -DRB1 allele match, n (%)
6/6 5 (4)
5/6 75 (52)
4/6 64 (44)
Infused TNC  107/kg, median (range)
Larger unit 2.56 (1.42-11.33)
Smaller unit 1.94 (0.91-7.09)fludarabine-based conditioning as described previ-
ously [2], with the exception of 4 patients, in whom
the fludarabine was substituted by clofarabine.
Thirty-four patients received high-dose myeloablative
conditioning, either hyperfractionated total body irra-
diation (TBI)-based (n 5 30) or a combination of clo-
farabine, melphalan, and thiotepa (n 5 4). Eighteen
patients received reduced-intensity myeloablative
conditioning with either cyclophosphamide 50 mg/
kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg, and
TBI 400 cGy (n 5 11), or melphalan 140 mg/m2 and
fludarabine 150 mg/m2 (n 5 7). Twenty patients re-
ceived nonmyeloablative conditioning with cyclophos-
phamide 50 mg/kg, fludarabine 150 mg/m2, and TBI
200 cGy. No patient received ATG. All patients re-
ceived calcineurin inhibitor–based graft-versus-host
disease (GVHD) prophylaxis (predominantly with
cyclosporine-A, aiming for a therapeutic level of
200-400 ng/mL) with mycophenolate mofetil begin-
ning on day -3. Mycophenolate mofetil was stopped
after day 45 or tapered over approximately 2 months
according to protocol in the absence of GVHD. Calci-
neurin inhibitor was continued at least 3 months post-
CBT, with subsequent taper in the absence of GVHD.
All patients received granulocyte colony-stimulating
factor support post-CBT. Double-unit grafts were
used to enhance engraftment in all patients.Prevention and Treatment of Infection
All patients were nursed in single high-efficiency
particulate air-filtered rooms and received quinolone-
based prophylaxis for neutropenia. Febrile neutropenia
was treated with vancomycin, piperacillin/tazobactam,
and either a quinolone or an aminoglycoside, unless
vancomycin-resistant enterococcus (VRE) colonization
was detected, in which case vancomycin was substituted
by linezolid until the results of blood cultures were
known [10]. During the study period, prophylaxis with
vancomycin from day -2 to at least day 7 was instituted
in recipients of myeloablative conditioning to prevent
Streptococcus viridans sepsis [11]. All patients received
micafungin for fungal prophylaxis during conditioning.
After transplantation, in adults this was switched to
a mold-active azole (voriconazole or posaconazole),
whereas in pediatric patientsmicafungin was continued.
Patients who developed a fever unresponsive to antibi-
otics or exhibited symptoms or signs suggestive of a
fungal infection were treated with a mold-active azole
or liposomal amphotericin.Mold-active fungal prophy-
laxis was administered to all patients with activeGVHD
requiring systemic corticosteroid therapy.
Prophylaxis against herpes simplex virus (HSV)
consisted of i.v. acyclovir 250 mg/m2 every 8 hours,
which was continued orally at discharge. Patients did
not receive routine prophylaxis against cytomegalovirus
(CMV), butweremonitored forCMVviremia by either
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treated preemptively. Pneumocystis jirovecii prophylaxis
was provided with sulfamethoxazole/trimethoprim or
i.v. pentamidine during conditioning, and aerosolized
pentamidine or atovaquone was restarted at approxi-
mately 1 month posttransplantation. Patients routinely
received i.v. immunoglobulin monthly for approxi-
mately 3 months starting at around day 30. Thereafter,
replacementwas guidedby IgG levels andwas triggered
by a total IgG of\500 mg/dL. Acyclovir therapy and
Pneumocystis prophylaxis were continued for at least
9 months in children and for 1 year in adults.
Definitions of Infection
Serious infections were collected prospectively for
each patient during the first year posttransplantation.
These infections were classified as described previ-
ously [12], with the exception that probable and possi-
ble fungal pneumonias without clinical compromise
were not automatically considered life-threatening by
definition, given the improved prognosis of these
infections with extended-spectrum azole therapy.
Thus, severe infections were those requiring i.v. ther-
apy and/or hospitalization. Life-threatening infections
were those that necessitated vasopressors or mechani-
cal ventilation and also included any viral pneumonias,
central nervous system human herpesvirus 6 (HHV6),
or Toxoplasma gondii infections. Lethal infections
either caused or contributed to death, whereas the
primary cause of death was defined according to the
algorithm of Copelan et al. [13]. Mild or moderate in-
fections, and positive blood cultures with coagulase-
negative Staphylococcus thought to be a contaminant,
were excluded. Clostridium difficile infections were
also excluded unless they were life-threatening or con-
tributed to death. Bacterial infections were either
proven or were presumed based on the combination
of clinical presentation plus response to treatment
with antibacterial antibiotics. Fungal infections were
defined as proven, probable, or possible according to
previously reported criteria [14]. An additional cate-
gory of ‘‘pneumonia’’ was included to capture patients
with fever and pulmonary infiltrates on chest com-
puted tomography scan consistent with either a bacte-
rial or fungal infection. These patients were treated
with combined antibacterial and antifungal therapy
and exhibited no evidence of a viral infection, but a spe-
cific etiology could not be determined. HHV6 viremia
was counted only if the patient received specific antivi-
ral therapy for HHV6. Recurrence intervals were de-
fined for viruses and molds as described previously
[12]. Patients were censored from the analysis of infec-
tions after day 30 if they had graft failure, and at the
time of relapse or disease progression, whereas surviv-
ing patients were included in the analysis of infections
in a particular time period only if they were followed
up for the entire time period.Measurement of Immune Recovery
Absolute lymphocyte count (ALC) was measured
from day 30 (67) posttransplantation, and ALC, circu-
lating lymphocyte subsets, T cell PHA-P proliferative
responses, and CMV complement fixation antigen re-
sponses (measured by thymidine incorporation using
standard methodology) were measured at 60 (67),
120 (615), and 180 (621) days and 1 year (645 days)
posttransplantation as described previously [15].
PHA-P responses were analyzed as the percentage of
the lower limit of normal (LLN).
Statistical Analysis
The probability of neutrophil and platelet engraft-
ment, acute GVHD, and transplantation-related mor-
tality (TRM) were computed using the cumulative
incidence function. For neutrophil engraftment and
acute GVHD, early death was the competing event,
whereas for TRM, death from relapse or disease pro-
gression was the competing event. Overall survival
and progression-free survival were calculated using
Kaplan-Meier methodology. The times to first bacte-
rial/fungal infection or viral infection were calculated
separately using a competing-risk analysis with early
death as the competing event. A univariate cause-
specific hazard Cox model was used to analyze the as-
sociation between potential risk factors and infection
risk. Exposure to systemic corticosteroids was analyzed
as a potential risk factor for infection and was defined
as treatment with at least 0.5 mg/kg methylpredniso-
lone or prednisone, or 9 mg/day budesonide, for 7 or
more consecutive days in the first posttransplantation
year. The infection risk factors for neutrophil recovery,
acute GVHD, corticosteroid exposure, and ALC/
CD3141 T cell recovery were assessed using a time-
dependent covariate cause-specific Cox hazard model.
Due to the small number of patients with more than
1 infection, a multivariate analysis to assess the total in-
fection burden was not performed. The Cochran-
Armitage trend test using the exact method was used
to assess whether CMV reactivation was associated
with a greater T cell response to CMV.RESULTS
Transplantation Outcomes
The cumulative incidence of sustained donor en-
graftment by day 45 was 94% (95% confidence interval
[CI], 85%-100%), with 4 patients experiencing graft
failure. The donor–recipient HLA-A antigen, -B anti-
gen, and -DRB1 allele match of the unit dominating in
engraftment in the 68 patients with sustained donor
engraftment was 6/6 in 1 patient, 5/6 in 38 patients,
and 4/6 in 29 patients, and themedian infused total nu-
cleated cell (TNC) dose was 2.14  107/kg (range,
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recovery was 23 days (range 11-43) in myeloablative
CBT recipients and 11 days (range, 7-36 days) in the
nonmyeloablative CBT recipients. The cumulative in-
cidence of grade II-IV acute GVHD at day 100 was
43% (95%CI, 33%-56%), with a distribution of 12 pa-
tients with grade II, 15 patients with grade III, and 4
patients with grade IV. At day 100 post-CBT, 20 of
60 evaluable patients (33%) had ongoing active late
acute GVHD necessitating therapy, chronic GVHD,
or an overlap syndrome. The day 180 TRM was 21%
(95% CI, 13%-33%). The Kaplan-Meier estimates of
overall survival and progression-free survival at 1 year
were 68% (95% CI, 57%-79%) and 59% (95% CI,
48%-71%), respectively. The primary causes of death
[13] were relapse (n 5 7), graft failure (n 5 3),
GVHD (n 5 6), organ failure (n 5 7), and infection
(n 5 2, both viral).Nature and Incidence of Serious Infections
The incidences of serious infections by type and
time period are summarized in Figure 1. There were
no infections due to Pneumocystis orToxoplasma. Nearly
three-quarters (72%) of infections occurred in the first
60 days. Some 61% of patients had 1 or more infec-
tions in the first 30 days post-CBT, 43% had 1 or
more infections between days 31 and 60, and 25%
had 1 or more infections between days 61 and 120.
Only 2 infections (both viral) directly caused death
according to the criteria of Copelan et al. [13], but 6 in-
fections contributed to death, with the primary causesFigure 1. Incidence of serious infections by type and time period in the
first year post-CBT. There was a marked decrease after day 60, although
a low but persistent risk of viral infection persisted during the first post-
transplantation year. Pneumonias due to a specific organism or diag-
nosed as due to a specific infection type (based on clinical
presentation, course, and response to therapy) are included under the
bacterial, fungal, and viral categories. The category of ‘‘pneumonias’’
had no organism identified and responded to combined antibacterial
and antifungal therapy, but a specific infection category could not be de-
termined. The drop in patient numbers is due to lack of complete follow-
up or patient death.of death in these cases being subsequent graft failure
(n 5 2), GVHD (n 5 3), and organ failure (n 5 1).
Thus, in 3 of the 6 patients who died of GVHD, bac-
terial (n 5 1) or viral (n 5 2) infection contributed to
death. All lethal infections were limited to the first 4
months posttransplantation. After day 120, serious in-
fections were uncommon, with 75% of patients free of
serious infections after this time.Bacterial and Fungal Infections
Forty-seven patients had a total of 75 bacterial or
fungal infections, or bacterial/fungal pneumonias. Of
these 47 patients, 28 patients had 1 infection (60%),
13 (28%) had 2 infections, and 6 (13%) had more
than 2 infections. The time to onset of the first bacte-
rial or fungal infection is shown in Figure 2.
The peak incidence of bacterial infections was in
the first 30 days posttransplantation (Figure 1). Spe-
cific details of the bacterial infections are provided in
Table 2 and Figure 3. Only 32 (59%) of infections
classified as bacterial had a documented organism.
These consisted predominantly of bacteremias (19
gram-positive and 10 gram-negative), with the most
common due to VRE. Of the 8 patients with VRE bac-
teremia, 6 were known to be colonized with VRE,
whereas 1 was not colonized and 1 was not tested. In
the majority of cases of presumed bacterial pneumonia
(n5 11; 92%), an organism was not identified, but re-
gardless, all affected patients were treated successfully
with antibacterial antibiotics. Most bacterial infections
were classified as severe, and bacterial infection con-
tributed to death in only 2 patients, including a patient
with Staphylococcus aureus septicemia (onset on day 7)
with subsequent graft failure and veno-occlusive dis-
ease, and a patient with grade IV acute GVHD of
the gut who died in the setting of fulminant C difficile
colitis.
The majority of fungal infections (10/13; 77%) oc-
curred in the first 30 days post-CBT, for an incidence
of 14% during this time period (Figure 1). All fungal210186420
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Figure 2. Cumulative incidence of first infection by etiology. Bacterial
and fungal infections had an earlier onset than viral infections.
Table 2. Number, Type, and Incidence of Serious Bacterial Infections by Posttransplantation Time Period
Time Period, Number
of Patients at Risk
Number of Infections; Patients
with One or More Infections Type Severity
Admittance to day 30, n 5 72 27 infections; 23/72 (32%) 11 gram-positive bacteremia: 5 VRE, 3 S viridans,
2 S aureus, 1 Bacillus sp
5 gram-negative bacteremia: 2 Escherichia coli; 1
Klebsiella sp; 1 Pseudomonas aeruginosa; 1
Stenotrophomonas maltophilia
1 Gardnerella vaginalis UTI
10 organisms unknown: 6 pneumonia; 3 sinusitis;
1 typhlitis
10 severe; 1 lethal*
5 severe
1 severe
10 severe
Day 31-day 60, n 5 67 12 infections; 10/67 (15%) 4 gram-positive bacteremia: 1 Enterococcus sp
(not VRE), 1 VRE, 1 Bacillus sp,
1 Micrococcus sp
1 gram-negative bacteremia: 1 S maltophilia
1 Mycobacterium (non-TB) pneumonia
6 organisms unknown: 3 pneumonia; 2 sinusitis;
1 typhilitis
4 severe
1 severe
1 life-threatening
6 severe
Day 61-day 120, n 5 65 7 infections; 7/65 (11%) 2 gram-positive bacteremia: 1 VRE, 1 S aureus
2 gram-negative bacteremia: 2 S maltophilia
1 C difficile colitis
2 organisms unknown: 1 tonsillitis; 1 pharyngitis
2 severe
2 severe
1 lethal*
2 severe
Day 121-day 180, n 5 47 5 infections; 5/47 (11%) 2 gram-positive bacteremia: 1 VRE; 1
coagulase-negative
Staphylococcus
2 gram-negative bacteremia: 1 E coli;
1 Haemophilus sp
1 organisms unknown: 1 sinusitis
2 severe
2 severe
1 severe
Day 180-1 year, n 5 36 3 infections; 3/36 (8%) 3 organisms unknown: 2 pneumonia; 1 sinusitis 3 severe
Some 72% of infections occurred in the first 60 days, the peak incidence was in the first 30 days, VRE bacteremia was the most common, and only 2
infections contributed to death.
*Infection contributed to death in 1 patient with S. aureus septicemia (onset day 7) with subsequent graft failure and veno-occlusive disease, and 1 patient
with grade IV acute GVHD of the gut who died in the setting of fulminant C. difficile colitis.
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severe. In only 1 patient was there a proven organism
(Saccharomyces cerevisiae pneumonia and fungemia).
The remaining infections classified as fungal based
on clinical presentation and response to therapy were
considered probable in 2 patients and possible in 10
patients, in accordance with published criteria [14].
The S cerevisiae infection resolved with micafungin
and voriconazole therapy, and all remaining patients
were treated successfully with mold-active therapy.Figure 3. Type and number of bacterial infections. Serious bacterial in-
fections decreased markedly after day 30 post-CBT.Pneumonias That Were Either Bacterial
or Fungal
Eight patients had pneumonias that responded to
combined antibacterial and antifungal therapy. Seven
of the 8 infections (88%) occurred in the first 30
days post-CBT, for an incidence of 10% (Figure 1).
Seven infections were severe, and 1 infection contrib-
uted to death in a patient who subsequently died of or-
gan failure. Combining these 8 cases of bacterial/
fungal pneumonia with those pneumonias classified
specifically as either bacterial (n 5 12) or fungal
(n 5 13) in nature resulted in a total of 33 bacterial/
fungal pneumonias. Seven of these 33 patients (21%)
underwent diagnostic bronchoscopy, but an organism
was identified in only 2 patients. However, all patients
but 1 were successfully treated with antibacterial and/
or antifungal therapy.Viral Infections
Forty-one patients had a total of 62 viral infections
(Table 3 and Figure 4). Of these 41 patients, 24 (59%)
had 1 infection, 15 (37%) had 2 infections, and 2 (17%)
had 4 separate viral infection episodes. In contrast to
bacterial/fungal infections, which diminished after
day 30 post-CBT, the incidence of viral infections in-
creased in the early postengraftment period (Table 3
and Figures 1, 2, and 4), with 30% of patients having
Table 3. Number, Type and Incidence of Serious Viral Infections by Time Period
Time Period, Patients at Risk
Number of Infections; Patients
with One or More Infections Type Severity
Admittance to day 30, n 5 72 19 infections; 15/72 (21%) 4 CMV: 2 viremia, 1 pneumonia*,
1 enteritis/colitis*
10 HHV6: 9 viremia, 1 encephalitis
4 BK hemorrhagic cystitis
1 adenovirus urinary tract infection
2 severe, 1 life-threatening,
1 lethal†
9 severe; 1 lethal†
4 severe
1 severe
Day 31-day 60, n 5 67 21 infections; 20/67 (30%) 15 CMV: 12 viremia, 1 pneumonia*,
1 enteritis/colitis*, 1 URI
1 HHV6 viremia
4 BK hemorrhagic cystitis
1 adenovirus enteritis/colitis*
13 severe, 1 life-threatening,
1 lethal†
1 severe
4 severe
1 lethal†
Day 61-day 120, n 5 65 10 infections; 10/65 (15%) 4 CMV viremia
1 adenovirus enteritis/colitis*
1 RSV URI
1 influenza URI
2 herpes zoster (single dermatome)
1 HSV mucositis
4 severe
1 lethal†
1 severe
1 severe
2 severe
1 severe
Day 121-day 180, n 5 47 6 infections; 6/47 (13%) 3 CMV viremia
1 EBV viremia
1 RSV pneumonia
1 influenza URI
3 severe
1 severe
1 life-threatening
1 severe
Day 180-1 year, n 5 36 6 infections; 6/36 (17%) 2 CMV viremia
4 EBV: 3 viremia, 1 non-Hodgkin lymphoma
2 severe
4 severe
RSV indicates respiratory syncytial virus; URI, upper respiratory infection.
The peak incidence was during 31-60 days post-CBT. CMV was the most common infection, and lethal infections were limited to the first 120 days post-
CBT.
*Patients with pneumonia or gut disease also had viremia.
†Five patients had lethal viral infections: 1 CMV pneumonia and 1 HHV6 encephalitis directly contributed to death, whereas in 3 patients viral infections
contributed to death (1 patient with early-onset CMV infection who subsequently had graft failure and 2 patients with adenovirus whose primary cause
of death was GVHD).
Biol Blood Marrow Transplant 17:1460-1471, 2011 1465Infection and Immune Recovery after Double-Unit CBT1 or more serious viral infections between day 31 and
day 60. Viral infections had the highest lethality,
with 2 viral infections (1 CMV pneumonia and 1
HHV6 encephalitis) directly causing death and 3
contributing to death (Table 3). These 5 lethal viral
infections occurred exclusively in the first 120 days
post-CBT, however; after this time, the incidence of
viral infections decreased, although nonlethal
infections remained a burden during the first yearFigure 4. Type and number of viral infections. Serious viral infections
decreased markedly after day 60 post-CBT. Notably, however, the inci-
dence remained stable between day 61 to 1 year (see Figure 1), although
mortality from viral infections was limited to the first 120 days.post-CBT, affecting 13% of patients between day
121 and day 180 and 17% between day 180 and 1
year. The infectious agent was identified in all viral
infections, with the exception of 2 clinical diagnoses
of shingles due to varicella-zoster virus (VZV).
Twenty-three patients had a total of 28 episodes of
CMV infection. CMV accounted for 28 of the 62
(45%) serious viral infections and thus was the most
common viral infection identified in this study. CMV
reactivation occurred at a median of 46 days (range,
15-274 days) post-CBT. It was observed exclusively
in CMV-seropositive recipients, with 23/39 (59%) of
seropositive CBT recipients reactivating CMV. Eigh-
teen patients had CMV viremia alone (23 infection
episodes), 4 patients had CMV disease (2 pneumonias
and 2 enteritis/colitis), and 1 patient had upper
respiratory tract infection. Thus, 4/39 (10%) CMV-
seropositive patients developed end-organ CMV
disease of the lung or gastrointestinal tract. Twenty-
six CMV infections were treated successfully in 21 pa-
tients (91% of patients with CMV infection) with
induction therapy with ganciclovir (n 5 1), oral val-
ganciclovir (n 5 13), or foscarnet (n 5 12), whereas
CMV disease caused or contributed to death in both
cases with pneumonia.
The nextmost common viral infection (n5 11) was
HHV6. Viremia was treated successfully in 9 patients
with foscarnet, whereas 1 patient had secondary graft
failure possibly related to this infection and/or its
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alitis. Eight patients had BK virus‒associated hemor-
rhagic cystitis; 4 had grade II (macroscopic
hematuria), and 4 had grade III (hematuria with clots)
disease [16]. The cystitis resolved spontaneously in all
patients. Both HHV6 and BK virus infections were
limited to the first 60 days post-CBT.
Five patients (8% of seropositive patients) reacti-
vated Epstein-Barr virus (EBV), at a median of 215
days (range, 104-314 days) post-CBT. Four of these
patients had viremia, and 1 had widespread EBV-
related posttransplantation lymphoproliferative dis-
ease. All 4 patients with isolated EBV viremia were
treated successfully with rituximab, whereas the pa-
tient with lymphoma failed rituximab therapy but
was treated successfully with third-party EBV-specific
cytotoxic T lymphocytes [17].
Three patients developed adenovirus infections, 1
with a urinary tract infection and 2 with enteritis/coli-
tis. Adenovirus contributed to death in both cases of
gastrointestinal disease. The incidences of HSV or
VZV infections were low in the first year post-CBT,
as was the incidence of lower respiratory tract infec-
tions with seasonal viruses.
Immune Recovery
Recovery of the ALC, CD3141 and CD3181
T lymphocytes, and PHA-P responses for all patients
are shown in Figure 5. Some patients had sustained
low lymphocyte levels and low PHA-P responses for
at least 1 year post-CBT; however, the median ALC
of 800 cells/mL (range, 100-14,200 cells/mL) was
within the normal range (500-5300 cells/mL) by day
60. Moreover, the median CD3141 T cell count of
268 cells/mL (range, 20-753 cells/mL) was .200
cells/mL by day 120 and was at the lower limit of the
normal range (359-1570 cells/mL) by day 180. Theme-
dian CD3181 T cell count of 92 cells/mL (range,
8-2911 cells/mL) was approaching the LLN range
(98-1217 cells/mL) by day 180. Themedian PHA-P re-
sponse was 80% of the LLN (range, 3-236 cells/mL) by
day 120. Progressive immune recovery was seen in
both adult and pediatric patients (Figure 6).
CMV-specific immunity was investigated as amea-
sure of functional lymphocyte responses in 58 patients
starting at day 60. T cell responses to CMV were seen
as early as 60 days post-CBT. Although we cannot de-
termine whether the T cell responses were protective,
there was a highly significant association between
CMV reactivation and the development of CMV-
specific T cell responses (P\.0001) (Table 4).
Risk Factors for Developing First Infection
Univariate analysis demonstrated no correlations
between the time to first bacterial or fungal infection
(including bacterial/fungal pneumonias) and patientage, cell dose (infused TNC/kg or CD341 cell/kg
dose of the unit dominating in engraftment), donor‒
recipient HLA match (dominating unit 5-6/6 vs 4/6
HLA match), time to neutrophil recovery $0.5 
109/L, acute GVHD (grade 0-I vs grade II-IV), time
to ALC $500/mL, time to CD3141 T cell count
$200 cells/mL, or exposure to systemic corticosteroids
(Table 5). However, univariate analysis identified a de-
layed time to development of bacterial/fungal infec-
tion in recipients of nonmyeloablative conditioning
(hazard ratio [HR], 0.25; 95% CI, 0.11-0.57; P 5
.001), whichwas also significant (P5 .007) inmultivar-
iate analysis. Univariate analysis for the first viral infec-
tion (predominantly CMV viremia) demonstrated no
relationship with conditioning intensity (Table 5).
Univariate analyses identified recipient age and
CMV seropositivity as significant risk factors for the
first viral infection, but only CMV seropositivity was
confirmed on multivariate analysis (HR, 3.97; 95%
CI, 1.75-9.02; P 5 .001).
Relationship between Infection and GVHD or
Corticosteroid Exposure for Another Indication
Before day 120 post-CBT, 37/67 (55%) of serious
bacterial/fungal infections (including pneumonias) oc-
curred in patients with grade II-IV acute GVHD or
who received systemic corticosteroids for another
indication. Between day 120 and 1 year post-CBT,
a similar proportion of such infections (5/8; 63%)
occurred in this context. For serious viral infections,
29/50 (58%) occurred in patients with GVHD or
who received corticosteroids before day 120; however,
11/12 (92%) viral infections occurred in this setting
between day 120 and 1 year. Specifically, whereas
only 11/23 (48%) early CMV infections before day
120 occurred in patients with GVHD or receiving cor-
ticosteroids, all (5/5; 100%) late CMV infections after
day 120 occurred in this setting. All 5 cases of EBV
occurred in the context of treatment for GVHD
(n 5 3) or corticosteroid therapy for another indica-
tion (n 5 2). Similarly, both cases of gastrointestinal
infection with adenovirus occurred in patients with
severe GVHD.DISCUSSION
Even though CBT has been performed for 2 de-
cades, relatively little is known about the infection
risk and immune recovery posttransplantation. High
rates of infection have been reported with single-unit
CBT [18-20], and use of ATG has been linked to
a high risk for viral infections [5-9]. Furthermore,
little data are available on infection risk and immune
recovery after double-unit CBT. An improved under-
standing of infection risk and immune recovery is
critical to the implementation of more effective
Figure 5. ALC recovery (A), CD3141 T cell recovery (B), CD3181 T cell recovery (C), and PHA-P response (D) after double-unit CBT. Median ALC
counts were within the normal range by day 60 post-CBT, median CD3141 T lymphocyte counts were.200 cells/mL, and PHA-P responses were 80%
of the LLN by day 120 post-CBT. The dotted lines represent the normal ranges. The boxes represent the interquartile range, and the solid lines within the
boxes represent the median value. The closed circles represent outlier values .1.5 times the interquartile range.
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Moreover, immune recovery is of particular interest
not only from the standpoint of infection risk, but
also given the recently reported association between
decreased leukemic relapse and successful recovery of
immune responses against herpes viruses after CBT
[21].
The present study is the first published detailed
analysis of infection risk after double-unit CBT with-
out ATG to our knowledge. We found that serious
opportunistic infections remain a major problem.
However, although bacterial and fungal infections
were frequent, mortality from such infections was
rare. This is likely due to aggressive management of fe-
brile neutropenia, prophylaxis against and coverage of
mold infections, and possibly improved engraftmentwith double-unit grafts. The only risk factor that we
identified for the development of these early infections
was conditioning intensity. Nonmyeloablative condi-
tioning was associated with a delayed time to develop-
ment of bacterial/fungal infections, similar to that seen
in transplantation with other hematopoietic stem
cell sources [22]. In addition, there were no cases of
P. jirovecii pneumonia or T. gondii infection. Although
this success is significant, bacterial and fungal infec-
tions (including pneumonias) remain a significant
burden, especially after myeloablative conditioning.
More rapid neutrophil recovery after double-unit
CBT would be beneficial, and will require a larger
CB inventory, ex vivo expansion, or other strategies
[23]. Currently, the optimum prophylaxis for bacte-
rial infections is unclear, given the emergence of
Figure 6. Median ALC recovery (A), CD3141 T cell recovery (B), CD3181 T cell recovery (C), and PHA-P response (D) after double-unit CBTac-
cording to age. Progressive immune recovery is seen in both adult and pediatric patients.
1468 Biol Blood Marrow Transplant 17:1460-1471, 2011C. Sauter et al.gram-negative organisms resistant to quinolones and
the increasing incidence of other antibiotic-resistant
organisms, such as VRE. Clinical care would also be
considerably enhanced with the implementation of im-
provedmethods to establish the causative organism for
clinical pneumonias and strategies to prevent VRE
bacteremia in colonized patients.
Viral infections, in contrast,weremore likely to cause
or contribute to death. Whereas HSV and VZV infec-
tions were effectively prevented by acyclovir, as reported
with other hematopoietic stem cell sources [24,25],
CMV infections posed a challenge. Consequently,
close monitoring for CMV reactivation is imperative toTable 4. T Cell Response to CMV, Showing a Strong Association
a CMV-Specific T Cell Response
Number Tested According to Recipient
Serostatus and CMV Reactivation
Positive
CMV seronegative, n 5 27 2 (7%): day
CMV seropositive, no reactivation, n 5 12 6 (50%): day
CMV seropositive, reactivation, n 5 19 15 (79%): day
day 270, nallow rapid institution of preemptive therapy. We
found a similar incidence of CMV viremia and disease
post-CBT as has been reported previously [26-29],
indicating that CMV represents a significant risk after
double-unit CBTdespite the omission of ATG.Our ob-
servation that earlyCMV infection was not prevented by
the avoidance of ATG, and had no relationship with
GVHD, is consistent with the report of Beck et al. [29].
Furthermore, whereas CMV-specific T cell responses
developed as early as day 60 post-CBT, CMV contrib-
uted to early deaths in 2 patients. Our center does not
routinely prescribe CMV prophylaxis, given the risk of
myelosuppression from ganciclovir/valganciclovir andbetween Recipient CMV Reactivation and Development of
T Cell Response to CMV; First Time
Detected Posttransplantation P Value
180, n 5 1; day 270, n 5 1 <.0001
60, n 5 2; day 120, n 5 2; day 270, n 5 2
60, n 5 3; day 120, n 5 7; day 180, n 5 2;
5 1; 1 year, n 5 2
Table 5. Univariate Analysis Using a Cause-Specific Hazard Model of Time to First Infection According to Patient/Graft
Characteristics and Transplantation Outcome
Variable
Bacterial/Fungal Infections Viral Infections
HR 95% CI P HR 95% CI P
Recipient age 1.00 (0.98-1.01) .73 1.02 (1.00-1.04) .05
Recipient CMV seropositive NA NA NA 3.87 (1.88-7.95) .0002
Nonmyeloablative versus myeloablative
conditioning
0.25 (0.11-0.57) .001 0.59 (0.28-1.25) .17
HLA match, 4/6 versus 5-6/6 1.59 (0.88-2.90) .13 1.14 (0.60-2.14) .70
Log_TNC dose (dominating unit) 0.79 (0.37-1.70) .54 0.47 (0.20-1.12) .09
Log_CD34+ dose (dominating unit) 0.70 (0.45-1.08) .11 0.81 (0.54-1.21) .30
Neutrophil recovery* 0.39 (0.13-1.15) .09 1.10 (0.45-2.66) .84
Grade II-IV acute GVHD* 0.72 (0.19-2.75) .63 0.56 (0.18-1.74) .32
Corticosteroid exposure* 0.86 (0.30-2.49) .78 0.59 (0.23-1.56) .29
ALC 500 cells/mL* 0.50 (0.13-1.90) .31 0.41 (0.12-1.39) .15
CD3+4+ T cells 200 cells/mL* 0.35 (0.05-2.50) .30 0.29 (0.05-1.60) .16
NA indicates not applicable.
Nonmyeloablative conditioning was associated with a prolonged time to first bacterial/fungal infection, whereas recipient CMV seropositivity was as-
sociated with a reduced time to first viral infection.
*Time-dependent analysis.
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support the findings of Cohen et al. [30] that na€ıve
CB lymphocytes can relatively rapidly generate anti-
gen-specific responses, more effective and less toxic
CMV prophylaxis and treatment are needed [31]. In
addition, our CMV complement-fixation antigen re-
sponse is only a semiquantitative proliferation assay
that primarily evaluates CD41 T cell responses without
assessing the cytolytic function of cytotoxic T cell re-
sponses. More sophisticated measures of CMV-specific
T cell responses, such as intracellular cytokine-based
assays [32], would be of interest to more accurately
assess CD41 and CD81 CMV-specific T cell recovery,
especially comparing CBT with different methods of
GVHD prophylaxis.
The incidence of HHV6 viremia at our institution
[33] was higher than we report here; however, the pres-
ent study included only symptomatic patients or those
with a rapidly increasing viral load who received
HHV6 therapy. High rates of HHV6 viremia have
been observed after CBT [34-36], and this finding’s
uncertain significance is very problematic. Whereas 1
of our patients developed graft failure possibly
related to HHV6 viremia, as reported by Chevallier
et al. [36], and another died of HHV6 encephalitis
[37,38], some cases of asymptomatic viremia resolved
without therapy. A better understanding of the
clinical course of HHV6 is needed to differentiate
patients that may derive benefit from potentially
toxic antiviral therapy and those who may be safely
observed.
The incidences of infection with adenovirus and
EBV in the present study are lower than those previ-
ously reported after CBT [4,6,7,9], possibly due
to our omission of ATG from the conditioning
regimens. Notably, in our study both cases of
adenovirus enteritis and all cases of EBV infectionoccurred exclusively in the context of systemic
GVHD therapy or corticosteroid administration for
another indication. Thus, monitoring for EBV
reactivation is warranted in any CBT recipient
receiving systemic immunosuppressive treatment for
GVHD or corticosteroids for another reason, to
facilitate immediate preemptive therapy. Although
EBV viremia resolved with rituximab therapy in 4
patients, the 1 patient with EBV lymphoma required
third-party EBV-specific cytotoxic T lymphocytes
[17]. Both patients with adenovirus gut disease died,
and although the primary cause of death was
GVHD, these viral infections contributed to death.
Although we were unable to identify any signifi-
cant predisposing factors to the development of the
first viral infection other than recipient CMV seropos-
itivity, it is notable that mortality from all infections,
including viruses, was limited to the first 4 months
post-CBT, suggesting the development of sufficient
immune reconstitution to prevent serious infections
even in patients with ongoing GVHD. We used
ALC and CD3141 T cell counts as simple measures
of immune recovery, given that CD3141T cell recov-
ery is protective against opportunistic infections
[15,39]. We observed more rapid CD3141 T cell
recovery than that reported by 2 early studies of
ATG-based single-unit CBT [40,41] and 2 more
recent CBT series of single- or double-unit CBT in
32 patients each [8,9]. Komanduri et al. [8] reported
a median 6-month CD3141T cell recovery of approx-
imately 100 cells/mL after single-unit ATG-based
CBT, compared with the 356 cells/mL found in the
present study. Brown et al. [9] reported a similarly
low median 6-month CD3141T cell count of approx-
imately 100 cells/mL in adult reduced-intensity ATG-
based double unit CBT recipients. Furthermore, the
PHA-P responses in our patients (median 80% LLN
1470 Biol Blood Marrow Transplant 17:1460-1471, 2011C. Sauter et al.by day 120 post-CBT) exceeded those previously re-
ported in a single-unit ATG-based CBT series (me-
dian \50% LLN by 6 months) [40,41]. Although
such retrospective comparisons with published series
are limited by the confounding factors of potentially
differing patient populations and conditioning
regimens, they do suggest differences in immune
recovery in the absence of ATG. Interestingly,
whereas the omission of ATG did not prevent early
CMV, a benefit was manifest in a reduced risk of
later infections, such as EBV, adenovirus, or late
CMV, given that patients not exposed to GVHD
therapy or corticosteroids for another indication
were at no risk for EBV, adenoviral gut disease, or
late CMV. In contrast, patients with GVHD or
corticosteroid therapy were at significant risk for
infection, with 92% of late viral infections after day
120 post-CBT occurring in this context.
In summary, the mortality risk from bacterial and
fungal infections has been significantly abrogated by
antimicrobial agents aimed at preventing and treating
infection, and also possibly by the use of double-unit
grafts. Although the risk of bacterial/fungal infection
is higher in myeloablative conditioning compared
with nonmyeloablative conditioning, such infections
are unlikely to be lethal. Viral infections, especially
early CMV infections, remain challenging. However,
we show a reduced incidence of EBV and adenovirus
infections compared with published literature, possi-
bly due to our omission of ATG. Without ATG, we
have achieved a high rate of sustained engraftment.
Our incidence of GVHD is not prohibitive, although
it should be acknowledged that a significant minority
of patients will develop severe GVHD. Furthermore,
the mortality risk from infection was restricted to the
first 4 months post-CBT, with the reduced risk coinci-
dent with recovery of ALC, CD3141 and CD3181 T
cells, and PHA-P responses. Nonetheless, there is
a need for further improvement. This will require
more rapid neutrophil recovery and more effective
prevention of GVHD, ideally without the profoundly
T cell‒depleting effects of ATG. Improved antiviral
agents and investigation of cellular therapy to augment
antiviral immunity should also be a major priority in
CBT. The investigation of more sophisticated mea-
sures of immune recovery, such as T cell receptor rear-
rangement excision circles [8,9], T cell differentiation
[8], and T cell repertoire [41], also will be of great in-
terest in ATG-free double-unit CBT recipients, al-
though the absence of lethal infections after 4
months post-CBT is the most powerful surrogate
marker of immune recovery [4]. Our findings support
the use of double-unit CBT without ATG and can
serve as a baseline for the investigation of new strate-
gies to further prevent infection and augment immune
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